Emergent Biosolutions Reports Strong Q1 Results with Revenue Exceeding Guidance
Emergent Biosolutions (NYSE:EBS) reported first-quarter 2026 results that exceeded revenue guidance, driven by strong performance in medical countermeasures and cost reductions. The company highlighted a $140 million Canada agreement and other contract wins.
Topics: adjusted_ebitda balance_sheet earnings guidance medical_countermeasures revenue